Cover Image


Large Volume Injection Devices for Self-Administration

出版商 Greystone Research Associates 商品編碼 297898
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
自我施打用大量輸液設備 Large Volume Injection Devices for Self-Administration
出版日期: 2014年03月20日 內容資訊: 英文




  • 患者的自我施打趨勢
  • 藥物遞輸設備的演進
  • 賦能技術
  • 醫藥品開發趨勢


  • 數量、粘性
  • 一次包裝
  • 注射方式
  • 患者接口系統




  • 自體免疫性發炎性疾病
  • 血液疾病
  • 心臟疾病
  • 神經
  • 癌症
  • 代謝疾病
  • 多發性硬化症
  • 生殖健康
  • 呼吸系統疾病


  • 自我施打及病人依從性
  • 法規指導及產品認證
  • 醫藥品的差異化/市場能力


Product Code: LVJD467R

Greystone Research Associates is pleased to announce the publication of a new market study. Large Volume Injection Devices for Self-Administration: Products, Therapeutics, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for wearable devices capable of injecting or infusing therapeutic drugs in large volumes. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Large Volume Injectors and the Evolving Landscape for Injectable Drugs

Biological drugs continue to increase in terms of the absolute number of new approved drugs and as a percent of all approved drugs. In two of the largest (in terms of revenue) and fastest growing therapeutic segments - autoimmune diseases and oncology - the majority of drugs consist of monoclonal antibodies (mAbs). Therapeutic drugs consisting of proteins and peptides present unique drug packaging and delivery challenges. Often the dosing volume required to achieve a therapeutic effect requires the drug to be delivered via infusion, resulting in logistical, cost and safety issues. Drug developers and their delivery technology partners are attempting to address this limitation. The development of injectors capable of delivering drug volumes of 2 mL or higher subcutaneously is one promising method. This report examines this new class of devices and analyzes their potential impact on biological drug delivery.


What You Will Learn

  • What drugs are supplied or are being developed in large volume delivery devices, what are the device specifics, and who markets them?
  • Who are the large volume injection device suppliers, their product strategies and their capabilities?
  • What are the major factors driving large volume injectable/infusible drug delivery devices?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, material selection issues, technologies and market development issues for large volume injection devices?
  • What are the large volume injection device categories and what is their market potential?
  • What are the significant economic, technology, and regulatory factors affecting the market for large volume injectable/infusible drug delivery devices?

Table of Contents

Executive Summary

Large Volume Injectables Market Dynamics

  • The Trend toward Patient Self-Administration
  • Drug Delivery Device Evolution
  • Enabling Technology
  • Drug Development Trends

Large Volume Injectors for Self-Administration - Design Factors

  • Volumes and Viscosities
  • Primary Packaging
  • Injection Methodology
  • Patient Interface

Large Volume Delivery Devices

  • Unbranded Injector (Enable Injections)
  • Microinfusor (BD Medical)
  • Unbranded Injector (Roche)
  • OmniPod (Insulet - moving beyond Insulin)
  • SmartDose (West Pharmaceuticals)
  • SensePatch FD/SD (Sensile Medical)
  • PatchPump (SteadyMed)
  • Precision Therapy/Flex Therapy (Unilife)

Large Volume Injection Devices - Near-Term Products

  • Herceptin SC (Roche/Halozyme)
  • Furosemide (scPharmaceuticals/Sensile Medical)
  • GnRH (Ferring/Insulet)
  • Prostacyclin (SteadyMed)

Therapeutic Market Segment Analysis & Forecasts

  • Inflammatory Autoimmune Diseases
  • Blood Disorders
  • Cardiovascular
  • Neurology
  • Oncology
  • Metabolic Diseases
  • Multiple Sclerosis
  • Reproductive Health
  • Upper Respiratory Diseases

Market Factors

  • Self-Administration and Patient Compliance
  • Regulatory Guidance and Product Approvals
  • Drug Product Differentiation/Marketability

Company Profiles

Back to Top